hims compounded semaglutide reviews Doctor Reacts: & Hers Weight Loss Review (Ad + Program) —What They Get Right & Wrong Hims is in the crosshairs.

Last December, the Biden administration published an interim rule to allow Medicare and Medicaid to cover GLP-1 agonists for weight loss

Like all medications, it comes with some risks, but with the right plan and support, most side effects can be managed or avoided

Two additional trials, CREDENCE (canagliflozin) and DAPA-HF (dapagliflozin), evaluated alternative primary outcomes of renal events and HF events in patients with CKD stage 2/3 and chronic HF, respectively, and analyzed 3P-MACE as a secondary endpoint

New England Journal of Medicine, 384(11), 9891002

Gradual titration helps improve tolerability and reduces early discontinuation

Texas telehealth platforms typically set a minimum age of 18 even though the FDA approved tirzepatide for adolescents 12+ in late 2024 based on SURMOUNT-Pediatric data